Affinity Asset Advisors LLC Sells 50,000 Shares of Immatics (NASDAQ:IMTX)

Affinity Asset Advisors LLC decreased its position in Immatics (NASDAQ:IMTX) by 14.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 300,000 shares of the company’s stock after selling 50,000 shares during the quarter. Affinity Asset Advisors LLC owned about 0.35% of Immatics worth $3,486,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Baker BROS. Advisors LP lifted its holdings in shares of Immatics by 10.4% during the first quarter. Baker BROS. Advisors LP now owns 6,443,398 shares of the company’s stock worth $67,720,000 after buying an additional 604,545 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Immatics by 13.3% during the 4th quarter. Wellington Management Group LLP now owns 6,352,929 shares of the company’s stock worth $66,896,000 after purchasing an additional 747,772 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Immatics by 38.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,225,360 shares of the company’s stock worth $33,899,000 after purchasing an additional 891,191 shares during the period. Vestal Point Capital LP acquired a new stake in shares of Immatics in the fourth quarter valued at approximately $22,113,000. Finally, RA Capital Management L.P. acquired a new stake in Immatics during the first quarter worth approximately $18,392,000. Institutional investors and hedge funds own 64.41% of the company’s stock.

Immatics Price Performance

IMTX stock opened at $11.68 on Wednesday. The company’s 50-day moving average price is $11.78 and its two-hundred day moving average price is $11.56. Immatics has a 12 month low of $7.15 and a 12 month high of $13.77.

Immatics (NASDAQ:IMTX) last issued its earnings results on Tuesday, August 13th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.17. Immatics had a negative return on equity of 23.34% and a negative net margin of 103.99%. The firm had revenue of $20.19 million for the quarter, compared to the consensus estimate of $12.36 million. On average, sell-side analysts expect that Immatics will post -0.99 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Immatics in a report on Thursday, September 5th.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.